| Analysis | Metabolite Name | Measured Value | Units | Group | Timepoint | Gender | Age at start of study |
|---|---|---|---|---|---|---|---|
| GC POSITIVE ION MODE | lactamide | 20 | Counts | Synbiotic | Recovery (days 631-633) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 37 | Counts | Placebo | Recovery (days 631-633) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 43 | Counts | Synbiotic | Recovery (days 631-633) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 54 | Counts | Placebo | Recovery (days 631-633) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 64 | Counts | Synbiotic | Recovery (days 631-633) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 77 | Counts | Placebo | Recovery (days 631-633) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 79 | Counts | Placebo | Recovery (days 631-633) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 101 | Counts | Synbiotic | Recovery (days 631-633) | Male castrated | 3 |
| GC POSITIVE ION MODE | lactamide | 107 | Counts | Synbiotic | Recovery (days 631-633) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 112 | Counts | Synbiotic | Baseline (days 5-7) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 114 | Counts | Placebo | Baseline (days 5-7) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 116 | Counts | Placebo | Baseline (days 5-7) | Female spayed | 7 |
| GC POSITIVE ION MODE | lactamide | 149 | Counts | Synbiotic | Baseline (days 5-7) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 155 | Counts | Placebo | Baseline (days 5-7) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 161 | Counts | Placebo | Recovery (days 631-633) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 171 | Counts | Synbiotic | Recovery (days 631-633) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 180 | Counts | Placebo | Recovery (days 631-633) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 199 | Counts | Placebo | Recovery (days 631-633) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 205 | Counts | Synbiotic | Baseline (days 5-7) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 210 | Counts | Synbiotic | Baseline (days 5-7) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 216 | Counts | Synbiotic | Baseline (days 5-7) | Male castrated | 3 |
| GC POSITIVE ION MODE | lactamide | 233 | Counts | Synbiotic | Recovery (days 631-633) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 278 | Counts | Synbiotic | Completion of treatment (days 26-28) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 308 | Counts | Placebo | Baseline (days 5-7) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 330 | Counts | Placebo | Recovery (days 631-633) | Female spayed | 7 |
| GC POSITIVE ION MODE | lactamide | 363 | Counts | Synbiotic | Completion of treatment (days 26-28) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 384 | Counts | Placebo | Baseline (days 5-7) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 403 | Counts | Placebo | Baseline (days 5-7) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 413 | Counts | Placebo | Completion of treatment (days 26-28) | Female spayed | 7 |
| GC POSITIVE ION MODE | lactamide | 413 | Counts | Synbiotic | Completion of treatment (days 26-28) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 439 | Counts | Placebo | Completion of treatment (days 26-28) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 444 | Counts | Synbiotic | Completion of treatment (days 26-28) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 447 | Counts | Placebo | Baseline (days 5-7) | Female spayed | 8 |
| GC POSITIVE ION MODE | lactamide | 507 | Counts | Synbiotic | Baseline (days 5-7) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 541 | Counts | Placebo | Completion of treatment (days 26-28) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 583 | Counts | Placebo | Completion of treatment (days 26-28) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 604 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 620 | Counts | Synbiotic | Completion of treatment (days 26-28) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 625 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 635 | Counts | Synbiotic | Baseline (days 5-7) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 649 | Counts | Synbiotic | Completion of treatment (days 26-28) | Male castrated | 3 |
| GC POSITIVE ION MODE | lactamide | 668 | Counts | Synbiotic | Completion of treatment (days 26-28) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 674 | Counts | Placebo | Completion of treatment (days 26-28) | Male castrated | 6 |
| GC POSITIVE ION MODE | lactamide | 761 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 880 | Counts | Placebo | Completion of treatment (days 26-28) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 911 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1004 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1060 | Counts | Placebo | Baseline (days 5-7) | Male castrated | 5 |
| GC POSITIVE ION MODE | lactamide | 1394 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1525 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1679 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1703 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 1800 | Counts | Synbiotic | Completion of treatment (days 26-28) | Female spayed | 3 |
| GC POSITIVE ION MODE | lactamide | 1880 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 2760 | Counts | Synbiotic | Baseline (days 5-7) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 2802 | Counts | NA | NA | NA | - |
| GC POSITIVE ION MODE | lactamide | 2955 | Counts | Placebo | Completion of treatment (days 26-28) | Female spayed | 6 |
| GC POSITIVE ION MODE | lactamide | 3366 | Counts | Placebo | Completion of treatment (days 26-28) | Male castrated | 6 |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|